Not Signed In -
Alemtuzumab |
Campath |
Image:Alemtuzumab.png Alemtuzumab Systematic (IUPAC) name Humanized anti-CD52 antibody Identifiers CAS number ? ATC code ? PubChem ? DrugBank BTD00109 Chemical data Formula C6468H10066N1732O2005S40 Mol. weight 145453.8 g/mol Pharmacokinetic data Bioavailability ? Metabolism ? Half life ~288 hrs Excretion ? Therapeutic considerations Pregnancy cat. ? Legal status Routes ? Alemtuzumab (marketed as Campat ...
Wikipedia - [full article]
Alemtuzumab Clinical Trials
- A Pilot Study of Alemtuzumab (Campath) in Patients with Myelodysplastic Syndrome (MDS)
ClinicalTrials.gov Identifier: NCT00123721 - Recruiting
- Fludarabine and Alemtuzumab or Cyclophosphamide Followed by Peripheral Blood Stem Cell Transplant or Alemtuzumab in Treating Patients With Advanced or Progressive Chronic Lymphocytic Leukemia
ClinicalTrials.gov Identifier: NCT00462332 - Recruiting
Leukemia
- Alemtuzumab Induction in Islet Transplantation
ClinicalTrials.gov Identifier: NCT00175253 - Recruiting
Type 1 Diabetes
- Alemtuzumab to Treat Sporadic Inclusion Body Myositis
ClinicalTrials.gov Identifier: NCT00079768 - Active, not recruiting
Myositis, Inclusion Body
- Fludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients With Refractory or Relapsed B-Cell Chronic Lymphocytic Leukemia
ClinicalTrials.gov Identifier: NCT00086775 - Active, not recruiting
refractory chronic lymphocytic leukemia; B-cell Chronic Lymphocytic Leukemia
- Alemtuzumab/Fludarabine for Relapsed/Refractory B-CLL
ClinicalTrials.gov Identifier: NCT00206726 - Active, not recruiting
Leukemia, Lymphocytic, Chronic, B-Cell
- Fludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
ClinicalTrials.gov Identifier: NCT00143065 - Active, not recruiting
Lymphoma, Small Lymphocytic; Lymphocytic Leukemia, Chronic
- Phase II Study to Evaluate the Combination of Fludarabine, Cyclophosphamide, and Alemtuzumab in Patients with B-CLL
ClinicalTrials.gov Identifier: NCT00147901 - Recruiting
B-cell Chronic Lymphocytic Leukemia
- Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
ClinicalTrials.gov Identifier: NCT00262925 - Recruiting
Recurrent Adult Acute Lymphoblastic Leukemia
- Fludara plus Alemtuzumab (Campath, MabCampath) vs Fludara alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) patients
ClinicalTrials.gov Identifier: NCT00086580 - Recruiting
B-Cell Lymphocytic Leukemia
- Alemtuzumab in Treating Patients With Relapsed or Refractory Advanced Mycosis Fungoides or Sézary Syndrome
ClinicalTrials.gov Identifier: NCT00057967 - Recruiting
Cutaneous T-Cell Lymphoma; mycosis fungoides and Sezary syndrome
- Alemtuzumab in Treating Patients With Advanced Chronic Lymphocytic Leukemia That Did Not Respond to Previous Fludarabine
ClinicalTrials.gov Identifier: NCT00274976 - Active, not recruiting
Leukemia
- Alemtuzumab and Rituximab in Treating Patients With High-Risk, Early-Stage Chronic Lymphocytic Leukemia
ClinicalTrials.gov Identifier: NCT00436904 - Active, not recruiting
Leukemia
- Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia
ClinicalTrials.gov Identifier: NCT00061945 - Active, not recruiting
B-cell adult acute lymphoblastic leukemia; L1 adult acute lymphoblastic leukemia; L2 adult acute lymphoblastic leukemia; ...
- Study of Alemtuzumab to Treat Advanced Mycosis Fungoides/Sezary Syndrome
ClinicalTrials.gov Identifier: NCT00157274 - Recruiting
Mycosis Fungoides; Sezary Syndrome
- Fludarabine and Rituximab Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia
ClinicalTrials.gov Identifier: NCT00098670 - Active, not recruiting
B-cell Chronic Lymphocytic Leukemia; stage I chronic lymphocytic leukemia; stage II chronic lymphocytic leukemia; ...
- Fludarabine, Cyclophosphamide, and Alemtuzumab in Treating Patients With Recurrent or Metastatic Renal Cell Carcinoma (Kidney Cancer) Undergoing Allogeneic Stem Cell Transplantation
ClinicalTrials.gov Identifier: NCT00073879 - Active, not recruiting
Stage IV Renal Cell Cancer; recurrent renal cell cancer
- Alemtuzumab, Tacrolimus, and Methylprednisolone in Treating Acute Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant
ClinicalTrials.gov Identifier: NCT00109993 - Active, not recruiting
Breast Cancer; Endocrine Cancer; female reproductive cancer; Graft Versus Host Disease; hematopoietic and lymphoid cancer; Neuroblastoma
- Combination Chemotherapy Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia
ClinicalTrials.gov Identifier: NCT00278213 - Active, not recruiting
Leukemia
- A Pilot Study to Evaluate the Safety of Subcutaneous Alemtuzumab in Patients with B-Cell Chronic Lymphocytic Leukemia
ClinicalTrials.gov Identifier: NCT00162851 - Completed
B-CLL
- Alemtuzumab and Pentostatin In T-Cell Neoplasms
ClinicalTrials.gov Identifier: NCT00453193 - Recruiting
Lymphoma; Leukemia
- Combination Chemotherapy Plus Alemtuzumab Followed by Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
ClinicalTrials.gov Identifier: NCT00027560 - Active, not recruiting
childhood Hodgkin's lymphoma; childhood non-Hodgkin's lymphoma; Leukemia; Lymphoma; myelodysplastic and myeloproliferative diseases; ...
- Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients
ClinicalTrials.gov Identifier: NCT00183248 - Active, not recruiting
Kidney Transplantation; Kidney Disease; Kidney Failure
- Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL
ClinicalTrials.gov Identifier: NCT00330252 - Recruiting
Chronic Lymphocytic Leukemia
- Effectiveness and Safety of Campath in Combination with Tacrolimus Monotherapy to Prevent Kidney Graft Rejection
ClinicalTrials.gov Identifier: NCT00147381 - Active, not recruiting
Kidney Transplantation
- Pentostatin, Cyclophosphamide, and Rituximab Followed By Alemtuzumab in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia
ClinicalTrials.gov Identifier: NCT00074282 - Recruiting
refractory chronic lymphocytic leukemia; B-cell Chronic Lymphocytic Leukemia
- Alemtuzumab (Campath® (Registered Trademark)) to Treat T-Large Granular Lymphocyte Leukemia
ClinicalTrials.gov Identifier: NCT00345345 - Recruiting
Lymphoprofilerative Disorders
- Safety/Efficacy of Induction Agents with Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant Recipients
ClinicalTrials.gov Identifier: NCT00113269 - Active, not recruiting
Kidney Transplantation
- The Effectiveness of Alemtuzumab Combination With CHOP to Treat Patients Newly Diagnosed With PTCL
ClinicalTrials.gov Identifier: NCT00441025 - Recruiting
Peripheral T-Cell Lymphoma
- Alemtuzumab Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Mycosis Fungoides/Sezary Syndrome
ClinicalTrials.gov Identifier: NCT00047060 - Recruiting
Lymphoma
- Combination Chemotherapy, Total-Body Irradiation, and Alemtuzumab in Treating Patients Undergoing an Autologous Stem Cell Transplant for Stage I, Stage II, Stage III, or Stage IV Chronic Lymphocytic Leukemia
ClinicalTrials.gov Identifier: NCT00276809 - Active, not recruiting
Leukemia
- Fludarabine, Alemtuzumab, and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Donor White Blood Cell Infusion in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
ClinicalTrials.gov Identifier: NCT00416884 - Active, not recruiting
Leukemia
- Alemtuzumab in Treating Patients With HTLV-1 Associated Adult T-Cell Leukemia/Lymphoma
ClinicalTrials.gov Identifier: NCT00064155 - Recruiting
Lymphoma
- Alemtuzumab in Treating Patients With T-Cell Large Granular Lymphocyte Leukemia
ClinicalTrials.gov Identifier: NCT00365066 - Recruiting
Leukemia
- The Efficacy and Safety of Alemtuzumab in Auotoimmune Cytopenias
ClinicalTrials.gov Identifier: NCT00472433 - Recruiting
Autoimmune Cytopenias
- A Pilot Trial With Subcutaneous Alemtuzumab and Oral Fludarabinephosphate for the Determination of Safety, Efficacy and Molecular Profiling for the Prediction of Response
ClinicalTrials.gov Identifier: NCT00565981 - Recruiting
B-Cell Chronic Lymphocytic Leukemia
- Study of Alemtuzumab Versus Anti-Thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas Transplantation
ClinicalTrials.gov Identifier: NCT00331162 - Recruiting
Graft Rejection
- Alemtuzumab, Total-Body Irradiation, and Fludarabine Followed By Donor Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
ClinicalTrials.gov Identifier: NCT00040846 - Recruiting
childhood Hodgkin's lymphoma; childhood non-Hodgkin's lymphoma; hematopoietic and lymphoid cancer
- Alemtuzumab, Fludarabine, and Total-Body Irradiation Followed by a Donor Stem Cell Transplant in Treating Patients With Immunodeficiency or Other Nonmalignant Inherited Disorders
ClinicalTrials.gov Identifier: NCT00553098 - Recruiting
Precancerous/Nonmalignant Condition
- Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia in Partial Remission or Complete Remission
ClinicalTrials.gov Identifier: NCT00458523 - Recruiting
Leukemia
- Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation
ClinicalTrials.gov Identifier: NCT00543283 - Recruiting
Leukemia; Lymphoma; Hodgkin's Disease; Hematologic Neoplasms; Multiple Myeloma; Carcinoma, Renal Cell
- Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
ClinicalTrials.gov Identifier: NCT00555048 - Recruiting
Graft Versus Host Disease; Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
- Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis, Study One
ClinicalTrials.gov Identifier: NCT00530348 - Recruiting
Multiple Sclerosis, Relapsing-Remitting
- Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis, Study Two
ClinicalTrials.gov Identifier: NCT00548405 - Recruiting
Multiple Sclerosis, Relapsing-Remitting
- Low-Dose Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Allogeneic Stem Cell Transplantation in Treating Patients With Myeloproliferative Disorder or Myelodysplastic Syndrome
ClinicalTrials.gov Identifier: NCT00069992 - Recruiting
Polycythemia Vera; Essential Thrombocythemia; de novo myelodysplastic syndromes; previously treated myelodysplastic syndromes; ...
- Alemtuzumab Combined With Etoposide, Vincristine, Doxorubicin, Cyclophosphamide, and Prednisone in Treating Patients Who Have Not Received Chemotherapy For T-Cell or NK-Cell Lymphoma
ClinicalTrials.gov Identifier: NCT00072254 - Recruiting
Lymphoma
- Alemtuzumab, Fludarabine, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
ClinicalTrials.gov Identifier: NCT00118352 - Recruiting
childhood Hodgkin''s lymphoma; childhood non-Hodgkin''s lymphoma; Graft Versus Host Disease; hematopoietic and lymphoid cancer
- Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant
ClinicalTrials.gov Identifier: NCT00354120 - Recruiting
Acute Myeloblastic Leukemia; Lymphoblastic Leukemia; Myelodysplasia; Chronic Myeloid Leukemia; Myelofibrosis; Lympho-Proliferative Diseases
- Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders
ClinicalTrials.gov Identifier: NCT00301834 - Recruiting
Congenital Amegakaryocytic Thrombocytopenia; Diamond-Blackfan Anemia; Leukemia; Myelodysplastic Syndromes; Severe Congenital Neutropenia
- Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma
ClinicalTrials.gov Identifier: NCT00363090 - Recruiting
Lymphoma
- Safety of a Multitherapy Regimen Containing Alemtuzumab in Children and Adolescents After Kidney Transplantation
ClinicalTrials.gov Identifier: NCT00240994 - Recruiting
Kidney Failure, Chronic; Kidney Transplantation; Immunosuppression
- Fludarabine, Busulfan, and Alemtuzumab Followed By Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases
ClinicalTrials.gov Identifier: NCT00448357 - Recruiting
Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes
- Alemtuzumab and Cyclosporine in Treating Patients With Myelodysplastic Syndromes
ClinicalTrials.gov Identifier: NCT00217594 - Recruiting
Myelodysplastic Syndromes
- Alemtuzumab and Combination Chemotherapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Peripheral T-Cell Lymphoma
ClinicalTrials.gov Identifier: NCT00562068 - Recruiting
Lymphoma; Small Intestine Cancer
- Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas
ClinicalTrials.gov Identifier: NCT00453427 - Recruiting
Peripheral T-Cell Lymphomas
- Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant
ClinicalTrials.gov Identifier: NCT00410657 - Active, not recruiting
Breast Cancer; Chronic Myeloproliferative Disorders; Gestational Trophoblastic Tumor; Graft Versus Host Disease; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Neuroblastoma; Ovarian Cancer; Testicular Germ Cell Tumor
- Comparison of Alemtuzumab/Tacrolimus Versus Interleukin-2 Receptor (IL-2R) Monoclonal Antibody (MoAb)/Tacrolimus/Mycophenolate in Kidney Transplantation
ClinicalTrials.gov Identifier: NCT00246129 - Recruiting
Kidney Transplantation; Kidney Diseases; Kidney Failure
- Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients with Progressive B-Cell Lymphocytic Leukemia
ClinicalTrials.gov Identifier: NCT00046683 - Completed
B-cell Chronic Lymphocytic Leukemia
- Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia
ClinicalTrials.gov Identifier: NCT00328198 - Recruiting
B-Cell Chronic Lymphocytic Leukemia (B-CLL)
- HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab
ClinicalTrials.gov Identifier: NCT00349349 - Recruiting
B-Cell Chronic Lymphocytic Leukemia
- Fludarabine, Cyclophosphamide, and Rituximab or Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia
ClinicalTrials.gov Identifier: NCT00564512 - Not yet recruiting
Leukemia
- A Single-Arm Phase II Study of Alemtuzumab in Combination With High-Dose Methylprednisolone in CLL Patients With p53 Deletion
ClinicalTrials.gov Identifier: NCT00292760 - Not yet recruiting
Chronic Lymphocytic Leukaemia
- Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia
ClinicalTrials.gov Identifier: NCT00562328 - Not yet recruiting
Leukemia
- Alemtuzumab in Treating Patients With Waldenstrom's Macroglobulinemia
ClinicalTrials.gov Identifier: NCT00081068 - Completed
Waldenstrom's Macroglobulinemia
- T-Reg Cell Kinetics for Pts Receiving Alemtuzumab and Undergoing SCT From HLA Mismatched-Related or HLA Matched or Mismatched Unrelated Donors
ClinicalTrials.gov Identifier: NCT00578539 - Recruiting
Acute Leukemia; Chronic Leukemia; Advanced Hodgkin Lymphoma; Non Hodgkin Lymphoma; Myelodsyplastic/Myeloproliferative Disease
- Clofarabine, Melphalan, and Alemtuzumab Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Diseases
ClinicalTrials.gov Identifier: NCT00572546 - Recruiting
Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Precancerous/Nonmalignant Condition; Secondary Myelofibrosis
- Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia
ClinicalTrials.gov Identifier: NCT00065260 - Recruiting
Aplastic Anemia
- Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients with Hemoglobinopathies
ClinicalTrials.gov Identifier: NCT00153985 - Recruiting
Hemoglobinopathies; Sickle Cell Disease; Thalassemia
- Fludarabine Followed by Campath-1H in Treating Patients With Chronic Lymphocytic Leukemia
ClinicalTrials.gov Identifier: NCT00004857 - Active, not recruiting
stage II chronic lymphocytic leukemia; stage IV chronic lymphocytic leukemia; stage I chronic lymphocytic leukemia; ...
- Alemtuzumab to Treat Severe Aplastic Anemia
ClinicalTrials.gov Identifier: NCT00195624 - Recruiting
Relapsed or Refractory Severe Aplastic Anemia; Severe Aplastic Anemia
- Phase I Study of CHOP + Campath for T-Cell, Null Cell, or NK Cell Lymphoma
ClinicalTrials.gov Identifier: NCT00161590 - Active, not recruiting
T-Cell Lymphoma; NK cell lymphoma; Null cell lymphoma
- Improving the Results of Bone Marrow Transplantation for Patients with Severe Congenital Anemias
ClinicalTrials.gov Identifier: NCT00061568 - Recruiting
Congenital Hemolytic Anemia; Diamond-Blackfan Anemia
- Peripheral Stem Cell Transplantation Plus Monoclonal Antibody Therapy in Treating Patients With High-Risk Hematologic Cancer, Refractory Breast or Kidney Cancer, or Melanoma
ClinicalTrials.gov Identifier: NCT00004143 - Active, not recruiting
Breast Cancer; hematopoietic and lymphoid cancer; kidney and urinary cancer; skin tumor
- R-CHOP and Alemtuzumab in Patients With Chronic Lymphocytic Leukemia
ClinicalTrials.gov Identifier: NCT00504491 - Not yet recruiting
Chronic Lymphocytic Leukaemia; Patients Resistant to a Purine Analogous; Patients Relapsed With Purines Therapy
- Phase II Study of Alemtuzumab (Campath-1H) Monoclonal Antibody in Patients with Relapsed and Resistant Classical Hodgkin''s Disease
ClinicalTrials.gov Identifier: NCT00129753 - Completed
Hodgkin''s Disease
- Alemtuzumab With or Without Methotrexate and Mercaptopurine in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia
ClinicalTrials.gov Identifier: NCT00089349 - Completed
recurrent childhood acute lymphoblastic leukemia
- Low Dose Alemtuzumab for Consolidation and Maintenance of Patients With B-Cell Chronic Lymphocytic Leukemia
ClinicalTrials.gov Identifier: NCT00336206 - Not yet recruiting
B-Cell Chronic Lymphocytic Leukemia
- A Pilot Study to Determine the Safety of Campath-1H (Anti-CD52 Antibody) Therapy in Newly Diagnosed Subjects with Type 1 Diabetes Mellitus
ClinicalTrials.gov Identifier: NCT00214214 - Not yet recruiting
new onset type 1 diabetes mellitus
- Alemtuzumab Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia
ClinicalTrials.gov Identifier: NCT00006390 - Completed
stage III chronic lymphocytic leukemia; stage IV chronic lymphocytic leukemia; B-cell Chronic Lymphocytic Leukemia; ...
- Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
ClinicalTrials.gov Identifier: NCT00104975 - Completed
acute leukemia; atypical chronic myeloid leukemia; chronic leukemia; chronic myeloproliferative disorders; ...
- Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
ClinicalTrials.gov Identifier: NCT00085449 - Completed
acute leukemia; atypical chronic myeloid leukemia; chronic leukemia; myelodysplastic and myeloproliferative disease; Non-Hodgkin's Lymphoma; ...
- Transplantation of Hematopoietic Cells in Children with Severe Combined Immunodeficiency Syndrome
ClinicalTrials.gov Identifier: NCT00152100 - Completed
Severe Combined Immunodeficiency
- Rituximab plus CAMPATH in Patients with Relapsed/Refractory Low-Grade or Follicular, CD20-positive, B-cell NHL
ClinicalTrials.gov Identifier: NCT00077961 - Terminated
Non-Hodgkin's Lymphoma
- Subcutaneously Administered CAMPATH in CD52 Expressing Hematologic Malignancies
ClinicalTrials.gov Identifier: NCT00113048 - Terminated
Hematologic Malignancies
- Phase I/II Study of CAMPATH in Patients with Relapsing or Refractory Non-Hodgkin's Lymphoma
ClinicalTrials.gov Identifier: NCT00051701 - Terminated
Non-Hodgkins Lymphoma
Resources
- Alemtuzumab (Drug Digest)
- Campath (Drug Digest)
email this page
print this page
bookmark this page
feedback on this page
